Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

Pneumotactix

Enzymatic medicine

Pneumotactix is developing a medicinal enzyme that breaks downs capsular polysaccharide, the protective shield around harmful bacterium. The process has the potential to give the body’s immune system a new advantage in fighting severe illness.

The company’s technology has demonstrated the ability to protect against lethal Streptococcus, or Strep, and their current focus is a strain of Paenibacillus.

Pneumotactix is working to investigate the potential toxicity and immunogenicity of the enzyme and is exploring ways to optimize its production.